117 related articles for article (PubMed ID: 22844354)
1. Advantages of the quenching probe method over other PCR-based methods for detection of the JAK2 V617F mutation.
Ono A; Okuhashi Y; Takahashi Y; Itoh M; Nara N; Tohda S
Oncol Lett; 2012 Aug; 4(2):205-208. PubMed ID: 22844354
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of different methodologies to detect the
Didone A; Nardinelli L; Marchiani M; Ruiz ARL; de Lima Costa AL; Lima IS; Santos NM; Sanabani SS; Bendit I
Pract Lab Med; 2016 Apr; 4():30-37. PubMed ID: 28856190
[TBL] [Abstract][Full Text] [Related]
3. Validating the Sensitivity of High-Resolution Melting Analysis for JAK2 V617F Mutation in the Clinical Setting.
Lin CY; Ho CM; Tamamyan G; Yang SF; Peng CT; Chang JG
J Clin Lab Anal; 2016 Nov; 30(6):838-844. PubMed ID: 27169616
[TBL] [Abstract][Full Text] [Related]
4. Detection of the JAK2 mutation in myeloproliferative neoplasms by asymmetric PCR with unlabeled probe and high-resolution melt analysis.
Cao HC; Lin J; Qian J; Yao DM; Li Y; Yang J; Chen Q; Chai HY; Xiao GF
J Clin Lab Anal; 2011; 25(4):300-4. PubMed ID: 21786333
[TBL] [Abstract][Full Text] [Related]
5. Detection of the MYD88 mutation by the combination of the allele-specific PCR and quenching probe methods.
Nogami S; Kawaguchi-Ihara N; Shiratori E; Ohtaka M; Itoh M; Tohda S
Int J Lab Hematol; 2017 Apr; 39(2):163-168. PubMed ID: 28042684
[TBL] [Abstract][Full Text] [Related]
6. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY
J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
[TBL] [Abstract][Full Text] [Related]
7. Development and inter-laboratory validation of unlabeled probe melting curve analysis for detection of JAK2 V617F mutation in polycythemia vera.
Wu Z; Yuan H; Zhang X; Liu W; Xu J; Zhang W; Guan M
PLoS One; 2011; 6(10):e26534. PubMed ID: 22028900
[TBL] [Abstract][Full Text] [Related]
8. Accurate quantitation of JAK2 V617F allele burden by array-based digital PCR.
Kinz E; Leiherer A; Lang AH; Drexel H; Muendlein A
Int J Lab Hematol; 2015 Apr; 37(2):217-24. PubMed ID: 24963593
[TBL] [Abstract][Full Text] [Related]
9. Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR.
Waterhouse M; Follo M; Pfeifer D; von Bubnoff N; Duyster J; Bertz H; Finke J
Ann Hematol; 2016 Apr; 95(5):739-44. PubMed ID: 26931113
[TBL] [Abstract][Full Text] [Related]
10. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
11. Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases.
Rapado I; Albizua E; Ayala R; Hernández JA; Garcia-Alonso L; Grande S; Gallardo M; Gilsanz F; Martinez-Lopez J
Ann Hematol; 2008 Sep; 87(9):741-9. PubMed ID: 18575865
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the reannealing- instead of melting-curve in the detection of JAK2 V617F mutation by HRM method.
Moradabadi A; Fatemi A; Noroozi-Aghideh A
J Blood Med; 2019; 10():235-241. PubMed ID: 31413649
[TBL] [Abstract][Full Text] [Related]
13. Development of a high resolution melting analysis assay for rapid identification of JAK2 V617F missense mutation and its validation.
Moradabadi A; Farsinejad A; Khansarinejad B; Fatemi A
Exp Hematol Oncol; 2019; 8():10. PubMed ID: 31165012
[TBL] [Abstract][Full Text] [Related]
14. Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms.
Lee E; Lee KJ; Park H; Chung JY; Lee MN; Chang MH; Yoo J; Lee H; Kong SY; Eom HS
Ann Lab Med; 2018 Mar; 38(2):147-154. PubMed ID: 29214759
[TBL] [Abstract][Full Text] [Related]
15. Superiority of Droplet Digital PCR Over Real-Time Quantitative PCR for
La Rocca F; Grieco V; Ruggieri V; Zifarone E; Villani O; Zoppoli P; Russi S; Laurino S; Falco G; Calice G; Marinaccio A; Natalicchio MI; Albano F; Musto P
Diagnostics (Basel); 2020 Mar; 10(3):. PubMed ID: 32150880
[No Abstract] [Full Text] [Related]
16. [Usefulness of real-time semi-quantitative PCR, JAK2 MutaScreen kit for JAK2 V617F screening].
Chae H; Lee JH; Lim J; Jung SW; Kim M; Kim Y; Han K; Cho BS; Cho SG; Lee JW; Min WS
Korean J Lab Med; 2009 Jun; 29(3):243-8. PubMed ID: 19571623
[TBL] [Abstract][Full Text] [Related]
17. Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2 V617F mutant allele detection.
Zapparoli GV; Jorissen RN; Hewitt CA; McBean M; Westerman DA; Dobrovic A
BMC Cancer; 2013 Apr; 13():206. PubMed ID: 23617802
[TBL] [Abstract][Full Text] [Related]
18. [The impact of autophagy on proliferation of HEL cells and hematopoietic cells of polycythemia vera patients with JAK2 V617F mutation].
Dong L; Shen X; Wei W; Shi W; Zhang G; Cao W; Li D
Zhonghua Xue Ye Xue Za Zhi; 2015 Jun; 36(6):520-5. PubMed ID: 26134021
[TBL] [Abstract][Full Text] [Related]
19. JAK2 46/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients.
Macedo LC; Santos BC; Pagliarini-e-Silva S; Pagnano KB; Rodrigues C; Quintero FC; Ferreira ME; Baraldi EC; Ambrosio-Albuquerque EP; Sell AM; Visentainer JE
Int J Lab Hematol; 2015 Oct; 37(5):654-60. PubMed ID: 25959311
[TBL] [Abstract][Full Text] [Related]
20. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
Borowczyk M; Wojtaszewska M; Lewandowski K; Gil L; Lewandowska M; Lehmann-Kopydłowska A; Kroll-Balcerzak R; Balcerzak A; Iwoła M; Michalak M; Komarnicki M
Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
